Global Atopic Dermatitis Drugs Market Size study & Forecast, by Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others) by Route of Administration (Topical, Injectable, Oral) and Regional Analysis, 2022-2029

Global Atopic Dermatitis Drugs Market Size study & Forecast, by Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others) by Route of Administration (Topical, Injectable, Oral) and Regional Analysis, 2022-2029

Global Atopic Dermatitis Drugs Market is valued at approximately USD 12.71 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 9.0% over the forecast period 2022-2029. Atopic dermatitis also known as eczema is a chronic, inflammatory skin, and non-contagious condition which affects the skin and leads to red, dry, itchy, and bumpy. The rise in awareness regarding the product availability for the disease, and robust product portfolio, coupled with the increasing expenditure on healthcare services and products are bolstering the market demand worldwide.

The rising incidences of atopic dermatitis is propelling the market demand across the globe. The Acta Derm Venereological Journal reported that in 2020 the doctor diagnosed that the prevalence of atopic dermatitis in adults varied from 17.1% in Europe to 10.2% in Asia; in children, the rates were 22.6% and 0.96%, respectively. Thereby, the high incidences of atopic dermatitis among the population are reinforcing the need for atopic dermatitis drugs to receive timely and suitable treatment, which, in turn, augments the growth of the market. Moreover, increasing product approvals, as well as the growing R&D investments by the key market players present various lucrative opportunities over the forecasting years. However, the high cost of therapeutics and some side effects associated with drugs are hindering the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Atopic Dermatitis Drugs Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing R&D investment and presence of well-established healthcare infrastructure. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the increase in pro-health initiatives, rise in consumer awareness, as well as strong healthcare reimbursement systems in the market space.

Major market players included in this report are:
Pfizer Inc.
Sanofi
AbbVie Inc.
GALDERMA LABORATORIES, L.P.
Eli Lilly and Company (Dermira)
Regeneron Pharmaceuticals Inc.
LEO Pharma Inc.
Otsuka Pharmaceutical Co., Ltd.
Novartis AG
Incyte Corporation

Recent Developments in the Market:
 In April 2021, AbbVie declared that the company is strengthening its supplemental New Drug Application (sNDA) to review RINVOQ for atopic dermatitis adolescent and adult patients. The Prescription Drug User Fee Act (PDUFA) was extended till quarter 3 of 2021.

Global Atopic Dermatitis Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Class, Route of Administration, , Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Class:
Corticosteroids
Calcineurin Inhibitors
PDE4 Inhibitors
Biologics
Others
By Route of Administration:
Topical
Injectable
Oral

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Pfizer Inc.
Sanofi
AbbVie Inc.
GALDERMA LABORATORIES, L.P.
Eli Lilly and Company (Dermira)
Regeneron Pharmaceuticals Inc.
LEO Pharma Inc.
Otsuka Pharmaceutical Co., Ltd.
Novartis AG
Incyte Corporation

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions